Randomised, double-blind, placebo-controlled, multi-centre, parallel group study to investigate the safety and tolerability as well as the immunological and clinical effects of multiple subcutaneous doses of DiaPep277 [Peptide-p277] in latent autoimmune diabetes in adults patients

Trial Profile

Randomised, double-blind, placebo-controlled, multi-centre, parallel group study to investigate the safety and tolerability as well as the immunological and clinical effects of multiple subcutaneous doses of DiaPep277 [Peptide-p277] in latent autoimmune diabetes in adults patients

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2007

At a glance

  • Drugs Peptide p277 (Primary)
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top